Evaluating liver type fatty acid binding protein as a diagnostic and prognostic biomarker in metabolic dysfunction-associated steatotic liver disease in pediatric patients
PLOS One · 30.09.2025 · 20 (9) · e0333581
DOI: 10.1371/journal.pone.0333581 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS One, online erschienen am 30.09.2025. Verfasst von Nadia Al Mazrouei und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Practice and Pharmacotherapeutics department, University of Sharjah, United Arab Emirates. Hauptthemen laut MEDLINE: Fatty Acid-Binding Proteins, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD), is a common liver disorder, predicted to increase globally. Currently, non-invasive methods are proposed for the assessment of (MASLD). This study aimed to investigate the use of serum Liver Type Fatty Acid Binding Protein (L-FABP) concentration as a diagnostic and prognostic biomarker in pediatric MASLD patients and to evaluate its relationship with steatosis and fibrosis.
Methods
An observational, cross-sectional study on paediatric MASLD patients. Serum levels of L-FABP and hepatic biochemical markers were measured and analyzed. Statistical analyses evaluated the association between L-FABP and other markers, while logistic regression and ROC curves assessed its diagnostic accuracy.
Results
Serum L-FABP levels showed a significant difference between the MASLD and control groups (P < 0.0001). The results of logistic regression revealed that each one-unit elevation of L-FABP level was associated with 144.5% higher odds of being MASLD (95% CI: 129.3% − 167.8%). A receiver operating characteristics (ROC) curve was constructed to assess the diagnostic accuracy of L-FABP. The resulted area under the ROC curve (AUC) was 0.885. The cutoff value was 5.7 ng/ mL, with sensitivity of 72.73%, and a specificity of 93.62%. The results also showed that the odds ratio of progressing from stage F2 to F3 increases by 108.9% (95% CI: 87.2% − 141.4%) for each one-unit increase in serum L-FABP level.
Conclusion
L-FABP shows promise as a non-invasive biomarker for diagnosing and monitoring MASLD in pediatric patients. Its association with disease stages suggests its utility in assessing disease progression, particularly in advanced stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacy Practice and Pharmacotherapeutics department, University of Sharjah, United Arab Emirates.
- Clinical Pharmacy department, New Giza University, Egypt.
- Pharmacology department, New Giza University, Egypt.
- Fellow of pediatric Hepatology, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
- Biochemistry and Molecular Biology Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
- Clinical Pharmacy department, New Giza University.
ORCID-Profile: Marafi Jammaa Ahmed, Ali Awadallah Saeed
Zitieren
APA
Al Mazrouei, N., ElGharbawy, M. M., Gamal, M., Emad, S., Mohamed, A. A., Ibrahim, O. M., Elnour, A. A., Ahmed, M. J., Beshir, S. A., Menon, V., Abdalla, S. F., Saeed, A. A., & ElRamly, H. A. (2025). Evaluating liver type fatty acid binding protein as a diagnostic and prognostic biomarker in metabolic dysfunction-associated steatotic liver disease in pediatric patients. PLOS One, 20(9), e0333581. https://doi.org/10.1371/journal.pone.0333581
Vancouver
Al Mazrouei N, ElGharbawy MM, Gamal M, Emad S, Mohamed AA, Ibrahim OM, et al. Evaluating liver type fatty acid binding protein as a diagnostic and prognostic biomarker in metabolic dysfunction-associated steatotic liver disease in pediatric patients. PLOS One. 2025;20(9):e0333581. doi:10.1371/journal.pone.0333581
BibTeX
@article{AlMazrouei2025,
author = {Al Mazrouei, Nadia and ElGharbawy, Mostafa Mohsen and Gamal, Mahitab and Emad, Shaimaa and Mohamed, Amal Ahmed and Ibrahim, Osama Mohamed and Elnour, Asim Ahmed and Ahmed, Marafi Jammaa and Beshir, Semira Abdi and Menon, Vineetha and Abdalla, Sami Fatehi and Saeed, Ali Awadallah and ElRamly, Heba Ali},
title = {Evaluating liver type fatty acid binding protein as a diagnostic and prognostic biomarker in metabolic dysfunction-associated steatotic liver disease in pediatric patients},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {9},
pages = {e0333581},
doi = {10.1371/journal.pone.0333581}
}
EUVIMED